Novel Agents and Combinations in Hodgkin Lymphoma
0 Pogledi
administrator
07/09/23
Panelists discuss novel agents, such as HDAC inhibitors, being explored in clinical trials for patients with Hodgkin lymphoma.
For more from this discussion, visit http://www.onclive.com/peer-exchange/lymphoma
Prikaži više
Komentari na Facebooku
Nema komentara